Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL425748 | 1.00 | HCAR2 (0.48) | HCAR2L3MBTL1MAPTTDP1CA12 | |
| SCHEMBL1581948 | 0.98 | HCAR2 (0.47) | HCAR2L3MBTL1MAPTTDP1CA12 | |
| SCHEMBL14363086 | 0.98 | HCAR2 (0.47) | HCAR2L3MBTL1MAPTTDP1CA12 | |
| SCHEMBL1581950 | 0.98 | HCAR2 (0.47) | HCAR2L3MBTL1MAPTTDP1CA12 | |
| SCHEMBL9744701 | 0.98 | HCAR2 (0.47) | HCAR2L3MBTL1MAPTTDP1CA12 | |
| SCHEMBL9744705 | 0.98 | HCAR2 (0.47) | HCAR2L3MBTL1MAPTTDP1CA12 | |
| SCHEMBL1126534 | 0.96 | HCAR2 (0.48) | HCAR2L3MBTL1MAPTTDP1CA12 | |
| SCHEMBL1126533 | 0.96 | HCAR2 (0.48) | HCAR2L3MBTL1MAPTTDP1CA12 | |
| SCHEMBL587678 | 0.93 | HCAR2 (0.43) | HCAR2L3MBTL1MAPTTDP1CA12 | |
| SCHEMBL7512241 | 0.92 | HCAR2 (0.52) | HCAR2L3MBTL1MAPTTDP1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120058609-A | Medicinal salt of (R) -5-cyclopentyl pyrazolidine-3-ketone, preparation method and application thereof | 四川科伦药物研究院有限公司 | 2025-05-30 | — | — | CN | disclosed |
| EP-2417121-A1 | 4, 5-DIHYDRO-1H-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES | Pfizer Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20120022058-A1 | 4,5-DIHYDRO-1H-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES | PFIZER INC. | 2012-01-26 | — | — | US | disclosed |
| EP-1585739-B1 | SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS | LILLY CO ELI (US) | 2011-04-20 | — | — | EP | disclosed |
| WO-2010116282-A1 | 4, 5-DIHYDRO-LH-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES | PFIZER INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-7576108-B2 | Substituted arylcyclopropylacetamides as glucokinase activators | ELI LILLY AND COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| US-20060111353-A1 | Substituted arylcyclopropylacetamides as glucokinase activators | ELI LILLY AND COMPANY | 2006-05-25 | — | — | US | disclosed |
| EP-1585739-A1 | SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS | ELI LILLY AND COMPANY (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004063179-A1 | SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111353-A1 | Substituted arylcyclopropylacetamides as glucokinase activators | GCK, GCKR, GALK1 | HCAR2 1938/4885L3MBTL1 4659/4885MAPT 4102/4885 |
| US-20120022058-A1 | 4,5-DIHYDRO-1H-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES | NR3C2, REN, AGTR1 | HCAR2 428/4885L3MBTL1 4869/4885MAPT 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.